.Attribute Medicine, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA authorization after an unfavorable test, which highlights the many complications as well as challenges of drug growth within this environment.